AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Suppression of HBV replication by a specific anti-viral compound

Detailed Technology Description: None

Others

*Abstract: Hepatitis B is a serious infection of the liver caused by the HBV virus. Worldwide, approximately 2 billion people have been infected with HBV and 1 million people die each year from HBV and its complications. 400 million worldwide and 1 million in the U.S. have chronic infection that may cause liver failure or liver cancer over time. HBV is also a serious concern for HIV patients. Up to 80% of HIV patients have been infected with HBV and 10% are chronically co-infected, the majority having an increased rate of liver failure. While many cases of HBV infection are cleared without intervention, treatments are needed when acute infections are aggressive and to prevent chronic infections to cause liver failure or liver cancer. Current treatment regimes have variable efficacy, consists of frequent injections, and are not able to clear the body of the virus. A new and potent inhibitor of HBV has the potential to be developed into a valuable treatment option for HBV patients.The current invention developed by researchers at the University of Missouri is a specific anti-viral compound that functions as an inhibitor of HBV replication. The compound is a considerably more potent inhibitor than the current anti-HBV drugs of preference and is a candidate for being used as a treatment for HBV infection and as a microbicide for prevention of HBV infection. POTENTIAL AREAS OF APPLICATIONSØ Treatment of acute aggressive hepatitis BØ Treatment of chronic hepatitis BØ Microbicide to prevent HBV infectionMAIN ADVANTAGES OF INVENTIONØ More potent than the leading anti-HBV agentsØ Potential to resolve a worldwide public health problemSTATE OF DEVELOPMENTMechanism of action known; tested in cell based assays; non-toxic in animal modelsLICENSING POTENTIALUniversity seeks development partner or licensee with potential to commercializePATENT STATUS: Patent application plannedTECHNOLOGY INNOVATORSStefan G. SarafianosTECHNOLOGY MANAGER CONTACTHarriet F. Francis, MS, JD; francish@missouri.edu; 573-884-0374

*Principal Investigator: Name: Stefan Sarafianos, Assistant Professor
Department:

Country/Region: USA

For more information, please click Here